Subscribe to Newsletter

Drug Discovery

Discovery & Development Drug Discovery

Rethinking Osteoarthritis With Extracellular Vesicles

| 4 min read

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

Discovery & Development Drug Discovery

Breaking Through Rare Diseases

| Stephanie Vine | 8 min read

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

Manufacture Advanced Medicine

The Risks and Rewards of Rare Diseases

| Stephanie Vine | 4 min read

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

Discovery & Development Clinical Trials

The Role of Data in Drug Development

| Daniel Chancellor | 4 min read

How connecting the data dots can lead to better development and clinical trals. 

Discovery & Development Drug Discovery

Characterizing RNA-Based Medicines

| Matthew Lauber, Andrew Argo, Elizabeth Foley | 5 min read

How precision analytics is driving the future of pharmaceuticals, from small molecules to CRISPR gene editing.

Discovery & Development Drug Discovery

Searching for a Lassa Fever Vaccine

| Stephanie Vine | 7 min read

A Lassa fever vaccine candidate shows promise in animal studies, with guinea pigs 100 percent protected from lethal virus exposure.

Business & Regulation Standards & Regulation

AMF’s 2026 AMR Strategy, Revealed

| Rob Coker | 3 min read

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Discovery & Development Drug Discovery

A New Computational Approach to Complex Molecule Synthesis

| Stephanie Vine | 8 min read

Early work from Scripps researchers uses a virtual library to synthesize plant-based metabolites: picrotoxanes.

Discovery & Development Drug Discovery

Breast Cancer Breakthrough

| Rob Coker

Scientists develop treatment that leads to complete regression of breast tumors in mice.

Business & Regulation Standards & Regulation

Researchers Respond to NIH Funding Cuts

| Stephanie Vine | 4 min read

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register